Scotiabank Raises Vertex Target to $660, Morgan Stanley Cuts to $660
Scotiabank raised its Vertex Pharmaceuticals target to $660, while Morgan Stanley cut its target to the same level and kept an Overweight rating.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that Scotiabank lifted its price target on Vertex Pharmaceuticals shares to $660 from $558. Morgan Stanley, meanwhile, trimmed its target to $660 from $665 and kept its Overweight rating. The ratings data is sourced from Benzinga.
why it matters
Analyst target revisions are routine and rarely move a stock on their own. Both brokers now point to the same $660 level, and Morgan Stanley still holds a positive view of the company.
tags
instruments
sources
- Vertex Pharmaceuticals Price Target Raised to $660.00/Share From $558.00 by Scotiabank — Dow Jones Newswires, 3 November 2026 at 17:50 UTC
- Vertex Pharmaceuticals Price Target Cut to $660.00/Share From $665.00 by Morgan Stanley — Dow Jones Newswires, 3 November 2026 at 17:54 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗